Tarceva-7631hkg.7z

Tarceva is a targeted therapy drug, specifically an EGFR inhibitor (Epidermal Growth Factor Receptor tyrosine kinase inhibitor).

It is used for locally advanced or metastatic NSCLC that has specific EGFR exon 19 deletions or exon 21 (L858R) substitution mutations. It is used for both first-line treatment and as maintenance therapy after previous chemotherapy. Tarceva-7631HKG.7z

While effective, Tarceva can cause significant side effects that require monitoring: Erlotinib (Tarceva) - Cancer Research UK Tarceva is a targeted therapy drug, specifically an

The Tarceva brand name has been discontinued in the U.S. in favor of generic alternatives, though the medication (erlotinib) remains in use. Primary Uses While effective, Tarceva can cause significant side effects

It works by blocking chemical signals that cause cancer cells to grow and divide.

It is approved for use in combination with gemcitabine chemotherapy for patients with advanced, previously untreated pancreatic cancer. Common Side Effects